Marina Biotech announced last week that it has closed its Cambridge, Mass., operations and is consolidating all of its research and development activities at its Bothell, Wash. headquarters.
The drug uses orally delivered attenuated Escherichia coli to transcribe shRNAs targeting beta-catenin, an oncogene that plays a role in the development of colorectal polyps that characterize the disease.
Through the transaction, MDRNA will gain Cequent's orally delivered transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.
The data, which were presented at this year's American Association for Cancer Research annual meeting, represent initial findings from the company's in-house effort to knock down multiple genes simultaneously and a collaboration related to multi-drug resistance of cancer cells.
